Navigation Links
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
Date:10/7/2009

DUBLIN, October 7 /PRNewswire-FirstCall/ --

- For Medical and Healthcare Media Only -

- Direct Comparison of the Two non-Calcium Phosphate Binders Gives new Insights Into Relative Efficacy

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

In this 12-week crossover study, patients (n=182) were randomized to receive either FOSRENOL or sevelamer for four weeks, and then switched to the alternative phosphate binder for the same period. Product doses were pre-defined to allow a direct efficacy comparison. Doses were based on those used in previous clinical trials[1,2] and established clinical practice.[3]

The study's primary endpoint, change in serum phosphorus from baseline to end of treatment, was evaluated using several statistical analyses; the primary analysis used last observation carried forward (LOCF) for the intention to treat (ITT) population (n=174), meaning that if a patient dropped out of the study during treatment, their last post baseline serum phosphorus measurement was used as the end of treatment value. The pre-determined key secondary analysis assessed the completer population; defined as those patients who had completed four weeks' treatment with both phosphate binders and had a serum phosphorus value at the end of treatment.[4]

The analysis of LOCF for the ITT population showed a numerically greater reduction in serum phosphorus with FOSRENOL (1.7mg/dL) versus sevelamer (1.4mg/dL), although
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. NASA study will help stop stowaways to Mars
7. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
10. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
11. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... has announced an exclusive contract with Trek Bicycle Corporation ... and Leum Software intend to enhance the current Ascend software ... help them manage their business with increased efficiency. , ,We ... successful. In the future, a dealers success will depend more ...
... effort to gather a burgeoning number of stem cell ... the University of Wisconsin-Madison has established the new Wisconsin ... of the UW-Madison Graduate School, the new initiative is ... efforts to develop new resources and opportunities for as ...
... Companies that do not specialize in software, but incorporate ... products, more often than not, overlook the importance of ... biggest feature or the most prevalent feature of the ... can and should be protected. , ,For example, ...
Cached Biology Technology:UW Madison launches new stem cell research program 2Beyond the screws and gears: Protecting your products by protecting your software 2
(Date:4/17/2014)... inhibits RSV infection , Respiratory syncytial virus ... tract infections, generating life-threating illness in very young ... are limited. RSV enters host cells through the ... fusogenic bundle. Small interfering peptides that prevent bundle ... peptides are highly susceptible to degradation. In this ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... one of the first efforts of its kind, UCLA researchers have ... showing not just the order in which genes fall in the ... findings, published in the August issue of the journal Genome ... and shed light on how they collaborate to help cells thrive ...
... mortality worldwide, accounting for more than one in ten deaths. ... million. The ESMO Congress provides a major international forum for ... Congress Program Highlights , , New ... new drugs to treat ovarian, skin, colorectal and other cancers, ...
... world is diagnosed with breast cancer every 23 seconds. It ... and approximately 456,000 die from the disease each year. At ... a scientist is taking aim at the molecular machinery behind ... G. Komen for the Cure, Catherine Denicourt, Ph.D., an assistant ...
Cached Biology News:UCLA scientists map all mammalian gene interactions 2UCLA scientists map all mammalian gene interactions 335th ESMO Congress media alert 235th ESMO Congress media alert 3
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Agarose Gel Loading Dye Mixture 6X...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Biology Products: